摘要
目的 探讨端粒酶活性及端粒酶相关组分 (hTERT)在乳腺癌诊断中的价值。方法 端粒重复扩增分析法检测 81例乳腺良恶性病变组织端粒酶活性 ;原位杂交法检测端粒酶逆转录酶基因hTERTmRNA的表达。结果 5 8例乳腺癌中 4 9例端粒酶阳性 (84 5 % ) ,端粒酶活性与临床病理参数无相关性 ;癌旁正常乳腺组织端粒酶阴性 ,7例乳腺增生症和 6例乳腺腺瘤中分别有 1例端粒酶阳性 ,与乳腺癌比差异非常显著 (P <0 .0 1)。原位杂交结果显示 ,hTERTmRNA阳性表达率为 6 7 2 % (39/ 5 8) ,与端粒酶活性表达呈一致性 (P <0 .0 5 )。结论 端粒酶活性检测和hTERTmRNA原位杂交检测在乳腺癌的诊断中具有重要参考价值 。
Objective To study the significance of telomerase activity and the expression of human telomerase transcripase (hTERT) mRNA in the diagnosis of breast carcinomas. Methods Telomerase activity was detected by telomeric repeat amplification protocol (TRAP) method, and hTERT mRNA by in situ hybridization. Results Telomerase activity was found in 49 of 58 (84.7%) cases of breast carcinomas by TRAP method. There was no correlation between telomerase activity and any parameter of clinical pathology. The telomerase activity of adjacent noncancerous tissues was absent, but the activity was detected in one of 6 (16.7%) cases of fibroadenoma and one of 7 (14.3%) cases of fibrocystic disease. There was a significant difference between breast carcinomas and other breast diseases (p<0.001). The positive rate of hTERT mRNA was 67.2% (39/48) in breast carcinomas, in which the positive particles were distributed in the cytoplasm of the tumor cells. Expression of hTERT mRNA was concordant with telomerase activity. Conclusions Detection of telomerase activity and hTERT mRNA is a valuable parameter in the diagnosis of malignant tumors. Telomease and its mRNA may be new targets in the treatment of breast carcinoma.
出处
《诊断病理学杂志》
CSCD
2002年第1期32-34,T007,共4页
Chinese Journal of Diagnostic Pathology
基金
吉林省科委基金 (990 5 65 -1)
关键词
端粒酶
乳腺肿瘤
TRAP
诊断
HTERT
Telomerase
Tumors, breast
Telomeric repeat amplification protocol
